Latest Filings

Issuer Activity

Overview :: Genomic Health, Inc. (OQ:GHDX) [?]
Business Focus: Biotechnology & Medical Research Share on StockTwits
Recent Price for GHDX
USD 31.050 0.000 (0.000)
NSQ Delayed 15 minutes
Feb 26 Close
1-Day High 52-Week High P/E 1-Day Volume Mkt Cap ($Mil)
31.250 37.745 N/A 98,687 984.96
1-Day Low 52-Week Low Yield Avg. Volume  
30.200 23.900 0.0% NSQ  
Log in or sign up for a free account to add this stock to your watch list. During beta also get free PDF company reports for US stocks.

Latest 10 SEC filings (by transaction date) for GHDX within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 7:24pm ET February 26th, 2015
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Feb 18/15 Feb 15/15 Popovits Kimberly J Direct Ownership Common Stock F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 -4,456  
Feb 18/15 Feb 15/15 Popovits Kimberly J Direct Ownership Common Stock A - Grant, award or other under Rule 16b-3(d) 2,430  
Feb 18/15 Feb 15/15 Shak Steven Direct Ownership Common Stock F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 -2,432  
Feb 18/15 Feb 15/15 Shak Steven Direct Ownership Common Stock A - Grant, award or other under Rule 16b-3(d) 1,750  
Feb 18/15 Feb 15/15 Cole G Bradley Direct Ownership Common Stock F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 -2,827 $31.12
Feb 18/15 Feb 15/15 Cole G Bradley Direct Ownership Common Stock A - Grant, award or other under Rule 16b-3(d) 1,840  
Feb 18/15 Feb 13/15 Shak Steven Direct Ownership Employee Stock Option (right to buy) Holding A - Grant, award or other under Rule 16b-3(d) 50,000  
Feb 18/15 Feb 13/15 Shak Steven Direct Ownership Common Stock A - Grant, award or other under Rule 16b-3(d) 8,500  
Feb 18/15 Feb 13/15 Cole G Bradley Direct Ownership Employee Stock Option (right to buy) Holding A - Grant, award or other under Rule 16b-3(d) 55,000  
Feb 18/15 Feb 13/15 Cole G Bradley Direct Ownership Common Stock A - Grant, award or other under Rule 16b-3(d) 9,000  
Sign up for a free account or login above to see all SEC filings within the past 6 months. During our beta offer, get free access to company PDF reports.
Latest 10 SEC filings (by filing date) for GHDX within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 7:24pm ET February 26th, 2015
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Feb 18/15 Feb 15/15 Popovits Kimberly J Direct Ownership Common Stock F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 -4,456  
Feb 18/15 Feb 15/15 Popovits Kimberly J Direct Ownership Common Stock A - Grant, award or other under Rule 16b-3(d) 2,430  
Feb 18/15 Feb 13/15 Shak Steven Direct Ownership Employee Stock Option (right to buy) Holding A - Grant, award or other under Rule 16b-3(d) 50,000  
Feb 18/15 Feb 15/15 Shak Steven Direct Ownership Common Stock F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 -2,432  
Feb 18/15 Feb 15/15 Shak Steven Direct Ownership Common Stock A - Grant, award or other under Rule 16b-3(d) 1,750  
Feb 18/15 Feb 13/15 Shak Steven Direct Ownership Common Stock A - Grant, award or other under Rule 16b-3(d) 8,500  
Feb 18/15 Feb 13/15 Cole G Bradley Direct Ownership Employee Stock Option (right to buy) Holding A - Grant, award or other under Rule 16b-3(d) 55,000  
Feb 18/15 Feb 15/15 Cole G Bradley Direct Ownership Common Stock F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 -2,827 $31.12
Feb 18/15 Feb 15/15 Cole G Bradley Direct Ownership Common Stock A - Grant, award or other under Rule 16b-3(d) 1,840  
Feb 18/15 Feb 13/15 Cole G Bradley Direct Ownership Common Stock A - Grant, award or other under Rule 16b-3(d) 9,000  
Sign up for a free account or login above to see all SEC filings within the past 6 months. During our beta offer, get free access to company PDF reports.
Sign up for a free account or login above to see the past 6 months of filings sorted by insider. During our beta offer, get free access to company PDF reports.
Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Key People
Kimberly J. Popovits
Chairman of the Board, President, Chief Executive Officer
G. Bradley Cole
Chief Financial Officer, Chief Operating Officer, Principal Financial Officer, Principal Accounting Officer
Steven Shak
Executive Vice President - Research and Development
Company Contact
Address: 301 Penobscot Drive
REDWOOD CITY CA 94063
Tel: N/A
Website: www.genomichealth.com
IR: See website
Business Overview
Genomic Health, Inc. (Genomic Health) is a molecular diagnostics company focused on the global development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions. Its Oncotype DX platform utilizes quantitative genomic analysis known as reverse transcription polymerase chain reaction (RT-PCR), in standard tumor pathology specimens to provide tumor-specific information, or the oncotype of a tumor. As of February 2012, Oncotype DX was evaluated in invasive breast cancer in 13 clinical studies involving more than 4,000 breast cancer patients worldwide. Genomic Health offers its Oncotype DX tests as a clinical service. In March 2012, the Company established a wholly owned subsidiary, InVitae Corporation.
Financial Overview
For the fiscal year ended 31 December 2014, Genomic Health, Inc. revenues increased 5% to $275.7M. Net loss increased 93% to $24.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Interest income decrease of 14% to $192K (income). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.42 to -$0.78.
Employees: 684 as of Dec 31, 2013
Reporting Currency: U.S. Dollars
Enterprise value: N/A
Annual revenue (TTM): $275.71M as of Dec 31, 2014
EBITDA (TTM): -$18.43M as of Dec 31, 2014
Net annual income (TTM): -$24.59M as of Dec 31, 2014
Free cash flow (TTM): N/A
Net Debt Last Fiscal Year: N/A
Shares outstanding: 31,721,630 as of Dec 31, 2014
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization
Competitors with Recent Insider Filings
Quintiles Transnational H (N:Q)
Seattle Genetics (OQ:SGEN)
Synageva Biopharma (OQ:GEVA)